No Data
No Data
Tonghua Dongbao Pharmaceutical (600867.SH) is preparing for the launch and market preparation of sitagliptin phosphate tablets. They will be shipped and sold in the near future.
Tonghua Dongbao (600867.SH) stated on the interactive platform on August 8th that the company is preparing for the launch and market preparation of its SGLT2 inhibitor product and will soon begin shipping and sales.
Tonghua Dongbao (600867.SH): Has repurchased 0.43% of shares accumulated.
On July 1st, Gelunhui reported that by the end of July 2024, Tonghua Dongbao (600867.SH) had cumulatively repurchased 8,617,117 shares through centralized bidding transactions, accounting for 0.43% of the company's current total share capital. The highest transaction price was 8.18 yuan/share, the lowest transaction price was 7.61 yuan/share, and the total amount of transactions was 67,977,902.54 yuan (excluding transaction fees).
Tonghua Dongbao (600867.SH): The first patient in China III clinical trial of Semaglutide Injection has been dosed.
Tonghua Dongbao (600867.SH) announced that in May 2024, the company and Peking Zhi Peptide Biomedical Science and Technology Co., Ltd. (hereinafter referred to as 'Peking Zhi Peptide') signed a strategic cooperation agreement.
1.4% Earnings Growth Over 5 Years Has Not Materialized Into Gains for Tonghua Dongbao Pharmaceutical (SHSE:600867) Shareholders Over That Period
Dongbao Pharma's Unit Doses First Subject for Weight Loss Drug Trial
Tonghua Dongbao (600867.SH): The phase Ib clinical trial of GLP-1/GIP dual-target receptor agonist (THDBH120 injection) for weight loss indication has completed the first dose administration of the subject.
On July 25th, Gelunhui announced that Tonghua Dongbao(600867.SH) has obtained the clinical trial approval notice for the weight loss indication drug injection THDBH120 issued by the Drug Evaluation Center(CDE) of National Medical Products Administration within China through its wholly-owned subsidiary Dongbao Zixing(Hangzhou) Biomedical Co., Ltd.("Dongbao Zixing") and has launched Phase Ib clinical trials. After obtaining the clinical trial approval of THDBH120 (weight loss indication) injection from the National Medical Products Administration, according to the relevant guidance for innovative chemical drugs within China, the applicant has initiated a clinical study for obesity in China.
No Data